Circulation Reports
Online ISSN : 2434-0790
JCS/JRC Emergency Cardiovascular Care Systematic Review Series 2025
Prognostic Impact of the Difference of Mechanical Circulatory Support in Patients With Acute Coronary Syndrome Complicated by Cardiogenic Shock ― A Systematic Review and Meta-Analysis ―
Katsutaka Hashiba Kazuo SakamotoAya Katasako-YabumotoTakeshi YamamotoNaoki NakayamaHiroyuki HanadaTakahiro NakashimaJin KirigayaTomoko IshizuYumiko HosoyaToru KondoYusuke OkazakiMasahiro YamamotoTakumi OsawaMarina AraiYoshio TaharaHiroshi NonogiTeruo NoguchiYasushi TsujimotoToshikazu FunazakiMigaku KikuchiTetsuya Matobafor the Japan Resuscitation Council (JRC) Cardiogenic Shock (CS) Task Force and the Guideline Editorial Committee on behalf of the Japanese Circulation Society (JCS) Emergency and Critical Care Committee
著者情報
ジャーナル オープンアクセス HTML
電子付録

2025 年 7 巻 11 号 p. 1014-1020

詳細
抄録

Background: The optimal device for mechanical circulatory support (MCS) in patients with acute myocardial infarction (AMI) complicated with cardiogenic shock (CS) remains unknown. Therefore, in this study we aimed to analyze which MCS (intra-aortic balloon pumping (IABP) or IMPELLA) is associated with better outcomes in patients with AMI-related CS.

Methods and Results: This systematic review and meta-analysis used a random-effects model to account for potential heterogeneity. Risk ratios (RRs) and 95% confidence intervals (CIs) were used for the dichotomous outcomes. The PubMed, Web of Science, and CENTRAL databases were searched up to April 30, 2023. The risk of bias was evaluated using the Revised Cochrane risk-of-bias tool for randomized trials (RoB2) tool, and the certainty of evidence was evaluated according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) tool. Two randomized controlled trials were included in the meta-analysis. For the primary outcome of 30-day survival, IMPELLA probably improves the outcome by a small amount compared with IABP (RR0.94 [95% CI 0.5–1.53], 29 fewer per 1,000 [95% CI from 204 fewer to 258 more], low certainty of evidence).

Conclusions: We could not show a survival benefit of IMPELLA compared with IABP in patients with AMI complicated by CS. Further investigation is required to resolve this issue.

Fullsize Image
著者関連情報
© 2025, THE JAPANESE CIRCULATION SOCIETY

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
前の記事 次の記事
feedback
Top